Tempest Therapeutics, Inc.
Public company- Headquarters
- BRISBANE, California
- Ticker
- TPST
- CIK
- 0001544227
WARN notices since 2024
Workers affected since 2024
Executive changes, last 12 months
Last event
Workers affected over time
Cumulative workers in WARN notices since 2024
Not enough notices to chart yet.
Leadership
| Role and person | Since | Change |
|---|---|---|
| CFOConstance Ames | Oct 30, 2026 | Departed |
| CFOStephanie Horn-Warnock | Oct 30, 2026 | Appointed |
| Class III directorJohn Frederick | Oct 19, 2026 | Appointed |
| CFOConstance Ames | Sep 28, 2026 | Appointed |
| CFOJustin Trojanowski | Aug 24, 2026 | Departed |
Related companies
Same industry and state, with recent events.
- ACADIA PHARMACEUTICALS INC
Executive Vice President, Head of Research and Development departs: Elizabeth H.Z. Thompson, Ph.D.
- KYNTRA BIO, INC.
Class III director appointed: Andrew E. Singer, MBA
- BIOMARIN PHARMACEUTICAL INC
WARN notice: Novato, CA
- CORCEPT THERAPEUTICS INC
President of Corcept Endocrinology departs: Sean Maduck
- Executive departure
CFO departs: Constance Ames
Constance Ames, Chief Financial Officer of Tempest Therapeutics, Inc., resigns the role, effective October 26, 2026. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Oct 30, 2026Role: Chief Financial Officer
- Executive appointment
CFO appointed: Stephanie Horn-Warnock
Stephanie Horn-Warnock was named Chief Financial Officer, Principal Financial and Accounting Officer, Treasurer, and Corporate Secretary of Tempest Therapeutics, Inc., effective October 26, 2026. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Oct 30, 2026Role: Chief Financial Officer, Principal Financial and Accounting Officer, Treasurer, and Corporate Secretary
- Executive appointment
Class III director appointed: John Frederick
John Frederick was named Class III director of Tempest Therapeutics, Inc., effective October 13, 2026. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Oct 19, 2026Role: Class III director
- Executive appointment
Class III director appointed: Nancy Freda-Smith
Nancy Freda-Smith was named Class III director of Tempest Therapeutics, Inc., effective September 22, 2026. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Sep 28, 2026Role: Class III director
- Executive departure
CFO departs: Nicholas Rossettos
Nicholas Rossettos, Chief Financial Officer of Tempest Therapeutics, Inc., resigns the role, effective September 22, 2026. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Sep 28, 2026Role: Chief Financial Officer
- Executive appointment
CFO appointed: Constance Ames
Constance Ames was named Chief Financial Officer Principal Financial and Accounting Officer, Treasurer, and Corporate Secretary of Tempest Therapeutics, Inc., effective September 22, 2026. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Sep 28, 2026Role: Chief Financial Officer Principal Financial and Accounting Officer, Treasurer, and Corporate Secretary
- Executive departure
CFO departs: Justin Trojanowski
Justin Trojanowski, Principal Financial Officer of Tempest Therapeutics, Inc., resigns the role, effective September 1, 2026. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Aug 24, 2026Role: Principal Financial Officer
- Executive appointment
CFO appointed: Nicholas Rossettos
Nicholas Rossettos was named Chief Financial Officer of Tempest Therapeutics, Inc., effective September 1, 2026. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Aug 24, 2026Role: Chief Financial Officer
Last verified Nov 8, 2026